- IN8bio's (INAB, Financial) INB-200 therapy achieved a 4-year remission for a patient with grade 4 IDH-mutant glioma.
- INB-200 demonstrated a median progression-free survival of 16.1 months, over double the standard-of-care 6.9 months.
- INB-200 is the first genetically modified gamma-delta T cell therapy evaluated in glioblastoma, showing favorable safety and potential benefits.
IN8bio Inc. (INAB), a clinical-stage biopharmaceutical company, has achieved a significant milestone in its Phase 1 trial of the INB-200 gamma-delta T cell therapy for glioblastoma (GBM). A patient treated with INB-200 has remained in remission for four years after being diagnosed with a grade 4 IDH-mutant glioma. The patient has maintained a good quality of life and has returned to work post-treatment, a substantial achievement in the treatment of such aggressive brain tumors.
The trial data reveals that INB-200 delivered a median progression-free survival (mPFS) of 16.1 months, which is more than double the 6.9 months typically observed with the standard-of-care Stupp protocol for newly diagnosed GBM. This improvement represents a 133% increase in mPFS, offering a promising new treatment direction that could outperform traditional methods that have seen little advancement in overall survival rates beyond 14-16 months over the past two decades.
INB-200 is the first genetically modified gamma-delta T cell therapy for glioblastoma, demonstrating a favorable safety profile and the potential for long-term benefits. This therapy could mark a breakthrough in GBM treatment by harnessing the unique properties of gamma-delta T cells, which might be particularly effective against solid tumors like GBM, where other immunotherapies have not succeeded.
